Clinical pharmacological studies on centpropazine--a new antidepressant compound.
Single oral doses of 10 to 160 mg centpropazine, a new antidepressant (synthesized by CDRI, Lucknow, India) were administered to groups of 4-5 male volunteers, each dose being interspersed with placebo in a double blind, non-crossover study by random distribution. The drug was well tolerated. Drowsiness, heaviness, weakness and/or headache were reported only at doses of 120 mg and above. No adverse effect was noted in various laboratory tests, ECG or vital parameters. In a multiple dose study, volunteers received 40 or 80 mg centpropazine daily for 4 wk. Mild restlessness and insomnia were observed in some subjects receiving 80 mg dose. In this study also no effect was observed in various laboratory tests, ECG or vital parameters.
Gupta
P P
PP
Asthana
O P
OP
Tangri
A N
AN
Dhawan
B N
BN
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines; D011897:Random Allocation
D000928:Antidepressive Agents; D010879:Piperazines; C044266:centpropazine